November 15, 2024 NEW YORK, NY — Eyenovia has shared that its Phase 3 CHAPERONE study is currently not meeting its primary...
January 18, 2024 NEW YORK — Eyenovia has regained the rights to MicroPine, an investigational eight microliter ophthalmic spray of atropine delivered by...
LAS VEGAS – “This category is about to explode, and you are so lucky to be at the forefront of myopia management,”...
November 1, 2020 By Thomas Aller, OD, FBCLA Collaborator, BHVI With the increasing incidence of myopia all around the world, predictions of...
Oct. 15, 2020 SYDNEY and LAVAL, QC – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye...
October 12, 2020 Bausch Health Companies and Eyenovia, Inc. (NASDAQ: EYEN) today announced that an affiliate of Bausch Health has acquired an...
August 11, 2020 NEW YORK and SHANGHAI, China — Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose...
August 11, 2020 Eyenovia, which in June enrolled its first patient in its Phase 3 CHAPERONE study of progressive myopia, this month...
June 24, 2020 By Dwight Akerman, OD, MBA, FAAO, FBCLA Chief Medical Editor, Review of Myopia Management The use of atropine to...
June 12, 2020 The clinical-stage ophthalmic biopharmaceutical company Eyenovia is developing a microdose treatment that is designed to improve the delivery of...